Intellectual Property India Publishes Patent Application for Use Of Tpl2 Inhibitors, Such As A Prodrug Of Tilpisertib, To Treat Inflammatory Bowel Disease Or Ulcerative Colitis

MUMBAI, India, June 30 -- Intellectual Property India has published a patent application (202617064207 A) filed by Gilead Sciences, Inc. on May 21, 2026, for Use Of Tpl2 Inhibitors, Such As A Prodrug Of Tilpisertib, To Treat Inflammatory Bowel Disease Or Ulcerative Colitis.

Inventors include Weber, Elijah J.; Othman, Ahmed A.; Chang, Ingrid J.; and Mckevitt, Matthew T..

The application for the patent was published on June 26, 2026, under issue no. 26/2026.

Abstract: The present disclosure relates generally to methods of using inhibitors of tumor progression locus 2 (TPL2) kinase for treating, stabilizing, or lessening the severity or progression of inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (U...